by The global wearable injectors market size is forecasted to hit from US$ 4.6 billion in 2021 to US$ 13.9 billion by 2030 and is anticipated to grow at compounded annual growth rate (CAGR) of 11.8% from 2021 to 2030, as per reports by market research and consulting organization Precedence Research.
The report contains 150+ pages with detailed analysis. The base year for the study has been considered 2021, the historic year 2017 to 2020, the forecast period considered is from 2021 to 2030.
The wearable injectors market is analyzed on the basis of value (US$ Million), volume (Unit), and price (US$/Unit). The report offers exclusive insights to help companies make informed decisions to sustain growth through the assessment period.
Download Free Sample Copy with TOC, Graphs & List of Figures @ https://www.precedenceresearch.com/sample/1402
The rapidly growing popularity of the wearable injectors among the patients owing to its benefits such as reduction in cost, self-administration of drugs, rising adoption of homecare facilities, and growing awareness regarding the wearable injectors across the globe is boosting the growth of the global wearable injectors market. Moreover, the increasing prevalence of chronic diseases and growing geriatric population are the significant drivers of the market. The old age population is more prone to chronic diseases like diabetes and CVDs.
The global cancer cases are estimated to grow by 47% from 2020 to 2040. It is expected that 28.4 million cases will be recorded in 2040, globally, according to the International Agency for Research on Cancer. According to the World Health Organization, the proportion of the global population above 60 years is expected to double from 12% to 22%, between 2015 and 2050. By 2030, around 16.67% of the global population will be aged 60 years or above. Hence, this is a major factor that is expected to be the crucial driver of the wearable injector market during the forecast period. Furthermore, the technological advancements in the biologics is encouraging the development of the drugs for the treatment of incurable diseases that needs special type of drug delivery devices.
Scope of the Wearable Injectors Market Report
| Report Highlights | Details |
| Market Size in 2030 | USD 13.9 Billion |
| Growth Rate | CAGR of 11.8% From 2021 to 2030 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Type, Application, End User, Region |
Competitive Intelligence
The report provides an understanding of the market composition and explains the role of established players and regional contributors. It is essential for the market players to make calculative moves and focus on client acquisition and retention. The detailed company profiles will provide the necessary intelligence to the reader. In order to maintain their share, the market players are focusing on strategies such as cross-border expansion, product differentiation and so on.
Some of the prominent players in the global wearable injectors market are listed as below:
- Amgen
- Becton, Dickinson and Company
- Dexcom, Inc.
- Enable Injections
- Insulet Corporation
- Sensile Medical
- Tandem Diabetes Care, Inc.
- Ypsomed
- F. Hoffmann-La Roche Ltd
- Johnson and Johnson Private Ltd
Market Dynamics
Drivers
The rising popularity and adoption of home healthcare is driving the market growth
The recent outbreak of the COVID-19 has resulted in a drastic change in the consumer behavior. Moreover, the rising awareness regarding the hospital acquired infections is shifting the healthcare delivery towards home healthcare across the globe. Therefore, the growing demand for the home healthcare is expected to fuel the adoption of the wearable injectors.
Restraints
High cost of the wearable injectors
The cost associated with the acquisition of the wearable injectors is high. Hence, the patients in the low and middle income countries struggle to acquire proper treatment that may increase their health risks. This is a major factor that restricts the market growth.
Opportunities
Increasing demand for the biologic
The development of various drugs in the biologics industry for the treatment of diseases such as cancer, CVD, and diabetes is expected to provide lucrative growth opportunities for the market players operating in the wearable injectors market. Further, the regulatory authorities like FDA and EMA are actively participating in monitoring the clinical trials, development, and approval of various new medicines, which will drive the market in the foreseeable future.
Challenges
Lack of awareness in the underdeveloped and developing regions
The low income of the consumers and less awareness regarding the wearable injectors among the population of the developing and underdeveloped nations is major challenge for the market players. Penetrating into the developing and underdeveloped markets is a challenging task for the players.
Regional Snapshot
North America dominated the global wearable injector market in 2020.The increased number of patients suffering from chronic diseases in the US has fostered the market growth in the region. According to a study, around 60% of the US population is suffering from at least one chronic diseases. Furthermore, the higher adoption rate of technologically advanced and innovative drugs among the North American population is spurring the demand for the wearable injectors. The rapidly growing biopharmaceutical industry is another significant driver of the market. The increased disposable income, increased awareness regarding the wearable injectors, and increased consumer expenditure on healthcare is expected to further drive the market growth.
Asia Pacific is estimated to be the most opportunistic market during the forecast period. The rising prevalence of chronic diseases and growing geriatric population in Asia Pacific is expected to be the major driver of the market. According to the World Health Organization, 80% of the global geriatric population will be living in the middle and low-income countries by 2050.The presence of several top biopharmaceutical companies in the nations like India, China, and South Korea is propelling the market growth. The presence of huge population and rising prevalence of chronic diseases among the population is a major factor that is expected to drive the growth of the drug delivery devices market in the region. Furthermore, the rising popularity of the personalized medicines among the population to treat incurable disorder may have a positive impact on the market.
Report Highlights
- Based on the type, the on-body segment dominated the market, accounting for over 55% of the market share in 2020. The on-body wearable injectors are much more efficient in administering the accurate amount of drugs in the body. The comfort and ease of use associated with the on-body injectors has fostered its adoption among the patients globally.
- Based on the application, the autoimmune diseases segment is estimated to be the most opportunistic segment during the forecast period. The rising prevalence of diabetes among the population and growing geriatric population is expected to drive the growth of this segment. According to the International Diabetes Federation, around 700 million people will be living with diabetes, by 2045.
- Based on the end user, the homecare segment dominated the market, garnering a market share of over 40% in 2020. The increasing demand for the self-injecting devices that reduces the healthcare costs and eliminates any medical assistance is the major factor that fostered the segment growth in the past few years.
Segments Covered in the Report
By Type
- On-Body
- Off-Body
- Hand Held
By Application
- Oncology
- Cardiovascular Diseases
- Infectious Diseases
- Autoimmune Diseases
- Others
By End User
- Hospitals
- Clinics
- Homecare
- Others
Regional Segmentation
– North America (U.S. and Canada)
– Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
– Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
– Latin America (Brazil and Rest of Latin America)
– Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Why should you invest in this report?
If you are aiming to enter the global wearable injectors market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for wearable injectors are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Buy Full Research Report, Click Here@ https://www.precedenceresearch.com/checkout/1402
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Wearable Injectors Market
5.1. COVID-19 Landscape: Wearable Injectors Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Wearable Injectors Market, By Product
8.1. Wearable Injectors Market, by Product Type, 2021-2030
8.1.1. On-Body
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Off-Body
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Hand Held
8.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Wearable Injectors Market, By Application
9.1. Wearable Injectors Market, by Application, 2021-2030
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Cardiovascular Diseases
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Infectious Diseases
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Autoimmune Diseases
9.1.4.1. Market Revenue and Forecast (2019-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Wearable Injectors Market, By End User
10.1. Wearable Injectors Market, by End User, 2021-2030
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Clinics
10.1.2.1. Market Revenue and Forecast (2019-2030)
10.1.3. Homecare
10.1.3.1. Market Revenue and Forecast (2019-2030)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Wearable Injectors Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2019-2030)
11.1.2. Market Revenue and Forecast, by Application (2019-2030)
11.1.3. Market Revenue and Forecast, by End User (2019-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.1.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.1.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.1.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.1.5.3. Market Revenue and Forecast, by End User (2019-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.3. Market Revenue and Forecast, by End User (2019-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.5.3. Market Revenue and Forecast, by End User (2019-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.6.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.6.3. Market Revenue and Forecast, by End User (2019-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2019-2030)
11.2.7.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.7.3. Market Revenue and Forecast, by End User (2019-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.3. Market Revenue and Forecast, by End User (2019-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.5.3. Market Revenue and Forecast, by End User (2019-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.6.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.6.3. Market Revenue and Forecast, by End User (2019-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2019-2030)
11.3.7.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.7.3. Market Revenue and Forecast, by End User (2019-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.5.3. Market Revenue and Forecast, by End User (2019-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.6.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.6.3. Market Revenue and Forecast, by End User (2019-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2019-2030)
11.4.7.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.7.3. Market Revenue and Forecast, by End User (2019-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.5.3. Market Revenue and Forecast, by End User (2019-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2019-2030)
11.5.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.5.4.3. Market Revenue and Forecast, by End User (2019-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2019-2030)
11.5.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.5.5.3. Market Revenue and Forecast, by End User (2019-2030)
Chapter 12. Company Profiles
12.1. Amgen
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Becton, Dickinson and Company
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Dexcom, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Enable Injections
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Insulet Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Sensile Medical
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Tandem Diabetes Care, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Ypsomed
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. F. Hoffmann-La Roche Ltd
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Johnson and Johnson Private Ltd
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1402
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
